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Synthesis of quinoxaline derivatives has attracted a great deal
of attention in view of their potent pharmacological activities.1
Approximately 1% of the world’s population is affected by
epilepsy.2 Therefore, investigation of new anticonvulsant is
still a challenge.
Most of the currently used anticonvulsant drugs are associ-
ated with adverse effects, such as sedation, ataxia and weight
loss or weight gain. Rare adverse effects can be life threatening
such as aplastic anemia.3 The development of safer and more
effective new anticonvulsant drugs is necessary.
It was reported that, the majority of anticonvulsant agents
mediates their effect through their action either by activation
of the c-aminobutyric acid (GABA) receptor or by inhibition
of the glutamate receptor.4 Glutamate receptors are classiﬁedinto two main subtypes, N-methyl-D-aspartate (NMDA) and
a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid
(AMPA) receptors.5
In fact, NMDA receptor antagonists may produce schizo-
phrenia-like symptoms, perceptual alterations, and memory
impairment; AMPA receptor antagonists have no such psy-
choactive properties.6
On the other hand, from the literature survey it was found
that many quinoxaline derivatives showed anticonvulsant
activity.7,8
Furthermore, Compounds 1 and 2a–d have shown high
afﬁnity toward AMPA receptor.8 Similarly; compound 3
(Fig. 1) was reported as a potent AMPA receptor antagonist.9
In the present work, it was decided to synthesize a series of
1,2,4-triazolo(4,3-a)quinoxalin-4-5H-one derivatives expected
to have AMPA receptor antagonistic activity. Beside, new
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to conﬁrm the chemical structure of the hydrazino derivative 8
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ethanol afforded the crystalline products of (9a,b), while reaction
with isatin in glacial acetic afforded (10). 5-Ethyl-1-mercapto-
1,2,4-triazolo[4,3-a]quinoxalin-4-5H-one (12), was prepared by
reaction of 1-ethyl-2-oxoquinoxalin-3-yl hydrazine (8) with car-
bon disulphide and potassium hydroxide in ethanol and then
treated with HCl. The reaction mixture was treated with appro-
priate alkyl chloroacetate and anhydrous potassium carbonate
in DMF to afford the corresponding alkyl (5-ethyl-4,5-dihy-
dro-4-oxo-1,2,4-triazolo [4,3-a]quinoxalin-1-ylthio) acetate
derivatives (13a,b). Potassium salt of 5-ethyl-1-mercapto-
1,2,4-triazolo[4,3-a]quinoxalin-4-5H-one (11) when treated
with chloroacetonitrile in DMF afforded 5-ethyl-4,5-dihydro-
4-oxo-1,2,4-triazolo[4,3-a]-quinoxalin-1-ylthioacetonitrile (14).
2.1. Docking study
All the target compounds were subjected to docking study to
explore their binding mode to AMPA receptor, since AMPA
is a target for a remarkable variety of anticonvulsant agents.8,11
All modeling experiments were performed using Discovery Stu-
dio program version 2.5. Each experiment used the biological
target coordinates downloaded from the Brookhaven website
(PDB: 1FTL).10 In order to qualify the docking results in terms
of accuracy of the predicted binding conformations in compar-
ison with the experimental procedure, the internal ligand (7,
8-dichloro-1-propyl-1,2,4-triazolo[4,3-a]quinoxalin-4-5H-one)
2c was used as a reference molecule. The docking study has
been conducted to predict the binding mode and to rationalize
the observed biological activity.
From the synthesized compounds, those having good bind-
ing opportunities according to docking experiments were sub-
jected to in vivo anticonvulsant evaluation on different groups
of mice. Compound 12 found to have the highest potency in
protection of animals against induced seizures. In order to
rationalize the high potency of this compound, docking into
the active site is illustrated in Fig. 2. The carbonyl group at po-
sition 4 established critical H-bond to THR-90 and ARG-96.2.2. Experimental
All melting points were taken on electrothermal (IA 9000
SERIS) digital melting point apparatus and are uncorrected.
IR spectra were recorded on Pye Unicam SP 1000 IR spec-
tro-photometer at Microanalytical Center, Cairo University.
The 1H NMR spectra were recorded in DMSO-d6 at
300 MHz, and 13C NMR spectra were recorded in DMSO-d6
at 75 MHz on a Varian Mercury VXR-300 NMR spectrometer
at Research Services Unit, Faculty of Science, Cairo Univer-
sity. Chemical shifts were related to those of the solvent. Tet-
ramethylsilane (TMS) was used as a standard. Mass spectra
were recorded on Hewlett Packard 5988 spectrometer at Re-
gional Center for Mycology and Biotechnology, Al-Azhar
University. Microanalyses were carried out at Microanalytical
Center, Cairo University. Progresses of the reaction were mon-
itored by tlc using tlc sheets precoated with UV ﬂuorescent sil-
ica gel Merck 60 F254 plates and were visualized using UV
lamp and n-hexane: ethyl acetate 9:1 as mobile phase.
N-Ethyl-2-nitroaniline (5), N-ethyl-O-phenylendiamine (6)
and 1-ethylquinoxaline-2,3(1H,4H)-dione (7) were prepared
according to the directions of Lin.12
2.2.1. 1-Ethyl-2-oxoquinoxalin-3-yl hydrazine (8)
A mixture of 1-ethylquinoxaline-2,3(1H,4H)-dione (7) (1.90 g,
0.01 mol) and hydrazine hydrate (10 mL) (50%), was reﬂuxed
for 2 h. After cooling, a crystalline product was obtained which
collected by ﬁltration, washed with water several times and
dried. Recrystallization of the resulting product from ethanol
afforded faint yellow crystalline needles, 1.93 g, (95%); mp:
165–167 C. IR: NH2 3339; CO 1645 cm1; 1H NMR: d 1.17
(t, 3H, CH3ACH2, J= 7.20 Hz), 4.15 (q, 2H, CH2ACH3,
J= 7.20 Hz), 4.52 (s, 2H, NH2) (D2O exchangeable), 7.17–
7.44(m, 4H, aromatic), and 8.68 (s, 1H, NH), (D2O exchange-
able); 13C NMR: d 12.30, (CH3, aliphatic), 36.44, (CH2,
aliphatic), 113.93, 123.34, 123.43, 125.13, 127.80, 133.87, (ben-
zene ring), 148.84 (amidic C‚O), 149.96 (C3 in quinoxaline
ring); Ms: m/z 204 (molecular ion) (100%), 189 (3.90%), 175
(13.62%), 145 (5.90%), 147 (28.47%). Anal. Calcd. for
C10H12N4O: C, 58.81; H, 5.92; N, 27.43. Found: C, 58.63; H,
5.80; N, 27.65.
2.2.2. General procedure for the reaction of 1-ethyl-2-
oxoquinoxalin-3-yl hydrazine (8) with different aromatic
aldehydes
All these reactions were carried out in ethanol. To a solution of
1-ethyl-2-oxoquinoxalin-3-yl hydrazine (8) (2.04 g, 0.01 mol)
in ethanol (10 mL), a solution of the appropriate aldehyde
(0.01 mol) in ethanol (5 mL), was added. The reaction mixture
was reﬂuxed for 5 h. The reaction mixture was ﬁltered while
hot and the ﬁltrate was allowed to stand overnight to give
the crystalline products of (9)a&b.
2.2.3. 3-(-2-Benzylidenehydrazinyl)-1-ethylquinoxalin-2-1H-
one (9a)
This compound was obtained as dark yellow needles, 2.90 g,
(90%); mp: 234–236 C; IR: NH 3240, CO 1642 cm1; 1H
NMR: d 1.24 (t, 3H, CH3ACH2, J= 7.20 Hz), 4.31 (q, 2H,
CH2ACH3, J= 6.90 Hz), 7.28–7.73(m, 9H, aromatic), 8.60
(s, 1H, NCH) and11.99 (s, 1H, NH); Ms: m/z 292 (molecular
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(M+AC6H5) (11.98%). Anal. Calcd. for C17H16N4O: C,
58.81; H, 5.92; N, 27.43. Found: C, 58.63; H, 5.80; N, 27.65.
2.2.4. 1-Ethyl-3-[2-(thiophen-2-
ylmethylidene)hydrazinyl]quinoxalin-2-1H-one (9b)
This compound was obtained as yellow crystals, 1.86 g, (60%);
mp: 218–220 C; IR: NH 3263, CO 1647 cm1; 1H NMR: d
1.23 (t, 3H, CH3ACH2, J= 7.20 Hz), 4.28 (q, 2H, CH2ACH3,
J= 6.90 Hz), 7.11–7.65(m, 7H, aromatic), 8.79 (s, 1H, NCH)
and 11.21 (s, 1H, NH); Ms: m/z 298 (molecular ion) (14.95%),
269 (M+ACH2CH3) (12.96%), 189 (M+AC4H3SCN) (100%).
Anal. Calcd. for C15H14N4OS: C, 60.38; H, 4.73; N, 18.78.
Found: C, 60.08; H, 4.56; N, 18.50.
2.2.5. (3Z)-1H-Indole-2,3-dione3-[(4-ethyl-3-oxo-3,4-
dihydroquinoxalin-2-yl)hydrazone] (10)
A mixture of 1-ethyl-2-oxoquinoxalin-3-yl hydrazine (8)
(2.04 g, 0.01 mol) and isatin, (1.47 g, 0.01 mol) was reﬂuxed
in glacial acetic acid (15 mL) for 6 h. The reaction mixture
was cooled to the room temperature. The orange precipitated
product was ﬁltered, washed with distilled water, dried and
crystallized from ethanol 80% to afford a faint yellow crystal-
line product, 3.09 g, (93%); mp: 275–277 C; IR: NH 3332,
CO 1653, 1708 cm1 (quinoxalinone and indolone, respec-
tively); 1H NMR: d 1.27 (t, 3H, CH3-CH2, J= 6.60 Hz),
4.25 (q, 2H, CH2ACH3, J= 7.20 Hz), 11.20 (s, 1H, NH),
6.94–7.73 (m, 8H, aromatic) and 13.67 (s, 1H, NH exchange-
able); Ms: m/z 333 (molecular ion) (18.97%), 304
(M+AC2H5) (100%), 276 (M+ACOC2H5) (8.83%). Anal.
Calcd. for C18H15N5O2: C, 64.86; H, 4.54; N, 21.01. Found:
C, 64.92; H, 4.54; N, 20.90.
2.2.6. Potassium salt of 5-ethyl-1-mercapto-1,2,4-triazolo[4,3-
a]quinoxalin-4-5H-one (11)
A mixture of 1-ethyl-2-oxoquinoxalin-3-yl hydrazine (8)
(2.04 g, 0.01 mol), carbon disulphide (0.76 g, 0.71 mL,
0.01 mol) and potassium hydroxide (0.56 g, 0.01 mol) was re-
ﬂuxed in ethanol (20 mL) for 2 h. The mixture was then al-
lowed to reach the room temperature to afford a faint yellow
precipitated product, 2.80 g, (98%); mp: >300 C; IR: CO
1656 cm1; Anal. Calcd. for C11H9KN4OS: C, 46.46; H, 3.19;
N, 19.70. Found: C, 46.58; H, 3.25; N, 19.84.
2.2.7. 5-Ethyl-1-mercapto-1,2,4-triazolo[4,3-a]quinoxalin-4-
5H-one (12)
A mixture of 1-ethyl-2-oxoquinoxalin-3-yl hydrazine (8)
(2.04 g, 0.01 mol), carbon disulphide (0.76 g, 0.71 mL,
0.01 mol) and potassium hydroxide (0.56 g, 0.01 mol) was re-
ﬂuxed in ethanol (20 mL) for 2 h. The mixture was then al-
lowed to reach the room temperature and poured onto 1N
HCl (20 mL). The yellow precipitated product was ﬁltered,
washed with distilled water and crystallized from ethanol
80% to afford 2.23 g (90%) of compound 12 as faint yellow
crystalline needles; mp: 285–287 C; IR: SH 2630, CO
1683 cm1; 1H NMR: d 1.25 (t, 3H, CH3ACH2,
J= 7.20 Hz), 4.24 (q, 2H, CH2ACH3, J= 7.20 Hz), 7.32–
7.63 (m, 4H, aromatic) and 14.77 (s, 1H, SH exchangeable);Ms: m/z 246 (molecular ion) (100%), 218 (M+ACO)
(74.81%), 204 (M+AC2H5) (5.75%). Anal. Calcd. for
C11H10N4OS: C, 53.64; H, 4.09; N, 22.75. Found: C, 53.29;
H, 3.96; N, 22.52.
2.2.8. General procedure for preparation of alkyl 2-(5-ethyl-4,5-
dihydro-4-oxo-1,2,4-triazolo[4,3-a]quinoxalin-1-ylthio)acetates
(13)
A mixture of 5-ethyl-1-mercapto-[1,2,4]triazolo[4,3-a]quinoxa-
lin-4(5H)-one (12) (2.46 g, 0.01 mol), appropriate alkylchlor-
oacetate (0.012 mol) and anhydrous potassium carbonate 1 g
was stirred in DMF (20 mL) for 1 h on a water bath. The mix-
ture was then poured onto ice cold water (100 mL) with con-
tinuous stirring. The white crystalline product was ﬁltered
and washed with distilled water (100 mL). Recrystallization
from ethanol 70% afforded the corresponding Alkyl 2-(5-
ethyl-4,5-dihydro-4-oxo-[1,2,4]triazolo[4,3-a]quinoxalin-1-
ylthio)acetate derivatives (13a&b).
2.2.9. Methyl-5-ethyl-4,5-dihydro-4-oxo-1,2,4-triazolo[4,3-a]
quinoxalin-1-ylthioacetate (13a)
2.38 g, (75%); mp: 157–159 C; IR: CO 1679, 1743 cm1
(amide and ester, respectively); 1H NMR: d 1.29 [t, 3H,
NCH2ACH3, J= 1.50 Hz], 3.70 [s, 3H, OCH3], 4.32 [q, 2H,
NCH2ACH3, J= 1.50 Hz], 4.46 [s, 2H, SCH2] and 7.50–7.75
[m, 4H, aromatic]; Ms: m/z 318 (molecular ion) (32.10%),
259 (M+ACOOCH3) (100%), 231 (M+ACOOCH3CO)
(60.06%); Anal. Calcd. for C14H14N4O3S: C, 52.82; H, 4.43;
N, 17.60. Found: C, 52.53; H, 4.77; N, 17.44.
2.2.10. Ethyl-5-ethyl-4,5-dihydro-4-oxo-1,2,4-triazolo[4,3-a]
quinoxalin-1-ylthioacetate (13b)
3.51 g, (95%); mp: 165–167 C; IR: CO 1677, 1737 cm1 (amide
and ester, respectively); 1H NMR: d 1.14 [t, 3H, NCH2ACH3,
J= 1.50 Hz], 1.20 [t, 3H, OCH2CH3, J= 1.20 Hz], 4.08 [q,
2H, NCH2ACH3, J= 1.50 Hz], 4.26 [q, 2H, OCH2CH3,
J= 1.20 Hz], 4.40 [s, 2H, SCH2] and 7.43–7.73 [m, 4H, aro-
matic]; Ms: m/z 332 (molecular ion) (27.83%), 259
(M+ACOOC2H5) (100%), 231 (M+ACOOC2H5CO)
(22.40%); Anal. Calcd. for C15H16N4O3S: C, 54.20; H, 4.85;
N, 16.86. Found: C, 52.53; H, 4.60; N, 16.94.
2.2.11. 5-Ethyl-4,5-dihydro-4-oxo-1,2,4-triazolo[4,3-a]
quinoxalin-1-ylthioacetonitrile (14)
A mixture of the potassium salt (11) (2.84 g, 0.01 mol) and
chloroacetonitrile (0.68 mL, 0.01 mol) in DMF (20 mL) was
heated on a water bath for 2 h. After cooling to the room tem-
perature, the reaction mixture was added to cold water
(200 mL) with continuous stirring. The white precipitated pro-
duct was ﬁltered, washed with water and crystallized from
methyl alcohol to produce 1.85 g (85%); mp: 231–233 C;
IR: CO 1666 (amide), C„N 2243 cm1; 1H NMR: d 1.27 (t,
3H, CH3ACH2, J= 6.90 Hz), 4.33 (q, 2H, CH2ACH3,
J= 6.90 Hz), 4.62 (s, 2H, SCH2) and 7.43–8.26 (m, 4H, aro-
matic); Ms: m/z 285 (molecular ion) (100%), 257 (M+ACO)
(61.66%), 242 (M+AC2H5N) (46.06%); Anal. Calcd. for
C13H11N5OS: C, 55.61; H, 4.67; N, 18.53. Found: C, 55.84;
H, 4.74; N, 18.87.
Table 1 Results of anticonvulsant evaluation for compounds
8 and 11–13.
Cpd. ID Dose
(mg/kg)
Protection
(%)
ED50
(mg/kg)
ED50
(mmol/kg)
R. P.*
Standard 12.5 100.00 6.25 0.02 1.00
6.25 50.00
3.12 16.67
8 200 83.33 129 0.63 0.04
100 33.33
50 16.67
11 25 66.67 12.5 0.05 0.48
12.5 50.00
6.25 16.67
12 25 66.67 12.5 0.04 0.60
12.5 33.33
6.25 16.67
13a 200 66.67 150 0.47 0.05
100 33.33
50 16.67
13b 200 100.00 95 0.29 0.09
100 66.67
50 16.67
* R. P. = Relative potency
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3.1. Anticonvulsant evaluation
Five compounds of the newly synthesized derivatives were se-
lected to be screened for their anticonvulsant activity on differ-
ent groups of mice. Phenobarbitone sodium was used as a
reference standard. The compounds to be tested or the stan-
dard phenobarbitone sodium were given by intraperitoneal
injection to a group of adult mice each group containing 6 ani-
mals. After 45 min pentylenetetrazole (as convulsion inducing
drug) was given intramuscularly in a dose of (60 mg/kg) body
weight. Convulsions began with jerks of the head and body of
the mouse consisting chieﬂy of clonic contractions. The sei-
zures ended either by depression or by complete recovery.13,14
The criterion of anticonvulsant activity is complete protec-
tion against convulsions of any kind. Observations were made
at least 60 min after the administration of pentylenetetrazole.
Doses that gave full protection against the induced convulsions
and that which exhibited 50% protection in addition to the
relative potencies of the test compounds to phenobarbitone
sodium were recorded in Table 1.4. Conclusion
From the results of docking study and biological evaluation, it
was noticed that, the presence of another aromatic system
attached to quinoxaline nucleus like 1,2,4-triazolo nucleus in-
creases the binding afﬁnity with AMPA receptor due to the
formation of favorable kind of interaction with the active site.
This effect was clearly seen in the higher relative potencies of
compounds 11 and 12. Compound 8 showed the lowest active
compound during biological evaluation. The higher reactivity
of the potassium salt 11 over compound 12 may be attributed
to the higher solubility of compound 11. Elongation of the ali-
phatic side chain in the ester derivatives 13 has a moderate ef-
fect on the activity.
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